Αρχική World News EMA Adopts a Positive Opinion for Biosimilar Denosumab World News EMA Adopts a Positive Opinion for Biosimilar Denosumab Από Ogkologos - 28 Μαΐου, 2025 886 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR New Treatment Helps Survivors Regain Sensation After Breast Cancer 21 Οκτωβρίου, 2020 EMA Recommends Granting a Conditional Marketing Authorisation for Futibatinib 28 Απριλίου, 2023 How a Musician Copes With Life With Metastatic Breast Cancer 17 Μαρτίου, 2021 Cancer Won’t Wait: “I prayed she would see her daughter start... 11 Οκτωβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... Study Offers Insights on Health Problems among AYA Cancer Survivors Joining the dots: How our new research data strategy will unlock...